The online version of this article (https://doi.org/10.1186/s13195-018-0340-8) contains supplementary material, which is available to authorized users.
Immunotherapy targeting the amyloid-β (Aβ) peptide is a promising strategy for the treatment of Alzheimer’s disease (AD); however, none of the active or passive vaccines tested have been demonstrated to be effective to date. We have developed the first active vaccine against the C-terminal end of Aβ40, ABvac40, and assessed its safety and tolerability in a phase I clinical trial.
A randomised, double-blind, placebo-controlled, parallel-group, phase I study of ABvac40 was conducted with patients aged 50–85 years with mild to moderate AD. Participants were entered into three separate groups according to time of study entry and were randomly allocated to receive ABvac40 or placebo (overall ratio 2:1). The first group received two half-doses of ABvac40 or placebo, whereas the second and third groups received two and three full doses, respectively. All treatments were administered subcutaneously at 4-week intervals. Patients, carers and investigators were blind to treatment allocation throughout the study. The primary objective was to assess the safety and tolerability of ABvac40 by registering all adverse events (AEs). All patients who received at least one dose of treatment were included in the safety analysis. The secondary objective was to evaluate the immunogenicity of ABvac40 by titration of specific anti-Aβ40 antibodies in plasma.
Twenty-four patients were randomly allocated: 16 patients to the ABvac40 group and 8 patients to the placebo group. All randomised patients completed the study, therefore the intention-to-treat and safety populations were identical. Overall, 71 AEs affecting 18 patients were recorded: 11 (69%) in the ABvac40 group and 7 (88%) in the placebo group (p = 0.6214). Neither incident vasogenic oedema nor sulcal effusion (amyloid-related imaging abnormalities corresponding to vasogenic oedema and sulcal effusions) nor microhaemorrhages (amyloid-related imaging abnormalities corresponding to microhaemorrhages and hemosiderin deposits) were detected throughout the study period in the ABvac40-treated patients. Eleven of 12 (~92%) individuals receiving three injections of ABvac40 developed specific anti-Aβ40 antibodies.
ABvac40 showed a favourable safety and tolerability profile while eliciting a consistent and specific immune response. An ongoing phase II clinical trial is needed to confirm these results and to explore the clinical efficacy of ABvac40.
ClinicalTrials.gov, NCT03113812. Retrospectively registered on 14 April 2017.
Additional file 1: Inclusion and exclusion criteria (detailed). (DOCX 16 kb)13195_2018_340_MOESM1_ESM.docx
Additional file 2 Randomisation (detailed). (DOCX 13 kb)13195_2018_340_MOESM2_ESM.docx
Additional file 3: Table S1. Frequency of adverse events (detailed). (DOCX 26 kb)13195_2018_340_MOESM3_ESM.docx
Additional file 4: Table S2. Relationship of adverse events (AEs) with the treatment. (DOCX 15 kb)13195_2018_340_MOESM4_ESM.docx
Additional file 5: Table S3. Quantification of Aβ40 and Aβ42 levels in plasma. (DOCX 14 kb)13195_2018_340_MOESM5_ESM.docx
Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M. World Alzheimer report 2015. The global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International; 2015. http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. Accessed 25 Apr 2017
Montanes M, Casabona D, Sarasa L, Pesini P, Sarasa M. Prevention of amyloid-β fibril formation using antibodies against the C-terminal region of amyloid-β 1-40 and amyloid-β 1-42. J Alzheimers Dis. 2013;34:133–7. PubMed
Pesini P, Lacosta AM, Sarasa M. The deposition of Aβ40 in the brain is pathognomonic for Alzheimer-type dementia in Down syndrome [abstract]. Alzheimers Dement. 2009;5(4 Suppl):297–8. CrossRef
Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm (Vienna). 2002;109:813–36. CrossRef
Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, et al. Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24. CrossRefPubMedPubMedCentral
Freeman GB, Lin JC, Pons J, Raha NM. 39-Week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. J Alzheimers Dis. 2012;28:531–41. PubMed
Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing Jr CB, et al. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol. 2013;36:14–23. CrossRefPubMed
Shin RW, Ogino K, Kondo A, Saido TC, Trojanowski JQ, Kitamoto T, et al. Amyloid β-protein (Aβ) 1–40 but not Aβ1–42 contributes to the experimental formation of Alzheimer disease amyloid fibrils in rat brain. J Neurosci. 1997;17:8187–93. PubMed
Montañés M, Marcos I, Canudas J, Lacosta AM, Pesini P, Sarasa M. Anti-Aβ x-40 antibodies exert neuroprotective effect against Aβ oligomer toxicity [abstract]. Alzheimers Dement. 2017;13(7 Suppl):1439–40. CrossRef
Mintun MA, Devous Sr.MD, Lu M, Pontecorvo MJ, Joshi AD, Southekal S, et al. Alzheimers Dementia. 2017;13 (7 supplement): P1452.
- Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
- BioMed Central